Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006

E Dannaoui; O Lortholary; D Raoux; M E Bougnoux; G Galeazzi; C Lawrence; D Moissenet; I Poilane; D Hoinard; F Dromer; YEASTS Group

doi:10.1128/AAC.01140-07

Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006

Antimicrob Agents Chemother. 2008 Feb;52(2):778-81. doi: 10.1128/AAC.01140-07. Epub 2007 Dec 10.

Authors

E Dannaoui¹, O Lortholary, D Raoux, M E Bougnoux, G Galeazzi, C Lawrence, D Moissenet, I Poilane, D Hoinard, F Dromer; YEASTS Group

Affiliation

¹ Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS URA3012, Institut Pasteur, 25, rue du Dr. Roux, 75724 Paris Cedex 15, France. dannaoui@pasteur.fr

Abstract

The in vitro activities of caspofungin and micafungin against 1,038 yeast isolates have been determined. The caspofungin and micafungin MICs were lower for Candida albicans, Candida glabrata, and Candida tropicalis than for Candida parapsilosis, Candida guilliermondii, and Candida krusei. A clear correlation was seen between the MICs for the two drugs.

Publication types

Comparative Study

MeSH terms

Antifungal Agents / pharmacology*
Candida / classification
Candida / drug effects
Caspofungin
Drug Resistance, Fungal
Echinocandins / pharmacology*
France
Humans
Lipopeptides
Lipoproteins / pharmacology*
Micafungin
Microbial Sensitivity Tests / standards
Mycoses / microbiology
Yeasts / classification
Yeasts / drug effects*

Substances

Antifungal Agents
Echinocandins
Lipopeptides
Lipoproteins
Caspofungin
Micafungin